PURPOSE: Limited data are available on the time course of treatment failures (recurrence and/or death), the nature and duration of adjuvant treatment benefit, and long-term recurrence rates in patients with resected stage II and III colon cancer. METHODS: The data set assembled by the Adjuvant Colon Cancer Endpoints Group, a collection of individual patient data from 18 trials and more than 20,800 patients testing fluorouracil-based adjuvant therapy in patients with stage II or III colon cancer, was analyzed. RESULTS: A significant overall survival (OS) benefit of adjuvant therapy was consistent over the 8-year follow-up period. The risk of recurrence in patients treated with adjuvant chemotherapy never exceeds that of control patients, signifying that adjuvant therapy cures some patients, as opposed to delaying recurrence. After 5 years, recurrence rates were less than 1.5% per year, and after 8 years, they were less than 0.5% per year. Significant disease-free survival (DFS) benefit from adjuvant chemotherapy was observed in the first 2 years. After 2 years, DFS rates in treated and control patients were not significantly different, and after 4 years, no trend toward benefit was demonstrated. This benefit was primarily driven by patients with stage III disease. CONCLUSION: Adjuvant chemotherapy provides significant DFS benefit, primarily by reducing the recurrence rate, within the first 2 years of adjuvant therapy with some benefit in years 3 to 4, translating into long-term OS benefit. This reflects the curative role of chemotherapy in the adjuvant setting. After 5 years, recurrence rates in patients treated on clinical trials are low, and after 8 years, they are minimal; thus, long-term follow-up for recurrence is of little value.
PURPOSE: Limited data are available on the time course of treatment failures (recurrence and/or death), the nature and duration of adjuvant treatment benefit, and long-term recurrence rates in patients with resected stage II and III colon cancer. METHODS: The data set assembled by the Adjuvant Colon Cancer Endpoints Group, a collection of individual patient data from 18 trials and more than 20,800 patients testing fluorouracil-based adjuvant therapy in patients with stage II or III colon cancer, was analyzed. RESULTS: A significant overall survival (OS) benefit of adjuvant therapy was consistent over the 8-year follow-up period. The risk of recurrence in patients treated with adjuvant chemotherapy never exceeds that of control patients, signifying that adjuvant therapy cures some patients, as opposed to delaying recurrence. After 5 years, recurrence rates were less than 1.5% per year, and after 8 years, they were less than 0.5% per year. Significant disease-free survival (DFS) benefit from adjuvant chemotherapy was observed in the first 2 years. After 2 years, DFS rates in treated and control patients were not significantly different, and after 4 years, no trend toward benefit was demonstrated. This benefit was primarily driven by patients with stage III disease. CONCLUSION: Adjuvant chemotherapy provides significant DFS benefit, primarily by reducing the recurrence rate, within the first 2 years of adjuvant therapy with some benefit in years 3 to 4, translating into long-term OS benefit. This reflects the curative role of chemotherapy in the adjuvant setting. After 5 years, recurrence rates in patients treated on clinical trials are low, and after 8 years, they are minimal; thus, long-term follow-up for recurrence is of little value.
Authors: N Wolmark; H Rockette; E Mamounas; J Jones; S Wieand; D L Wickerham; H D Bear; J N Atkins; N V Dimitrov; A G Glass; E R Fisher; B Fisher Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: M J O'Connell; J A Laurie; M Kahn; R J Fitzgibbons; C Erlichman; L Shepherd; C G Moertel; W I Kocha; R Pazdur; H S Wieand; J Rubin; A M Vukov; J H Donohue; J E Krook; A Figueredo Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Ian Chau; Mark J Allen; David Cunningham; Andrew R Norman; Gina Brown; Hugo E R Ford; Niall Tebbutt; Diana Tait; Mark Hill; Paul J Ross; Jacqui Oates Journal: J Clin Oncol Date: 2004-03-08 Impact factor: 44.544
Authors: N Wolmark; H Rockette; B Fisher; D L Wickerham; C Redmond; E R Fisher; J Jones; E P Mamounas; L Ore; N J Petrelli Journal: J Clin Oncol Date: 1993-10 Impact factor: 44.544
Authors: R M Goldberg; T R Fleming; C M Tangen; C G Moertel; J S Macdonald; D G Haller; J A Laurie Journal: Ann Intern Med Date: 1998-07-01 Impact factor: 25.391
Authors: C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick Journal: N Engl J Med Date: 1990-02-08 Impact factor: 91.245
Authors: Li-Qing Du; Xiao-Qing Du; Jian-Qiang Bai; Yan Wang; Qing-Shan Yang; Xiao-Chun Wang; Peng Zhao; Hong Wang; Qiang Liu; Fei-Yue Fan Journal: J Cancer Res Clin Oncol Date: 2012-01-25 Impact factor: 4.553
Authors: Aimery de Gramont; Joleen Hubbard; Qian Shi; Michael J O'Connell; Marc Buyse; Jacqueline Benedetti; Brian Bot; Chris O'Callaghan; Greg Yothers; Richard M Goldberg; Charles D Blanke; Al Benson; Qiqi Deng; Steven R Alberts; Thierry Andre; Norman Wolmark; Axel Grothey; Daniel Sargent Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: Neal W Wilkinson; Greg Yothers; Samia Lopa; Joseph P Costantino; Nicholas J Petrelli; Norman Wolmark Journal: Ann Surg Oncol Date: 2010-04 Impact factor: 5.344